Acetic Acid for the Detection of Esophageal Neoplasms
Reason given: not enough patients enrolled
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Coordinación de Investigación en Salud, Mexico
- Trial code
- NCT04054713
- Record updated
- 24 April 2025
- Original description
Barrett's esophagus is a complication of chronic gastroesophageal reflux disease that occurs in up to 10% to 15% of patients with this pathology. Well-defined risk factors have been established and are important because they are considered a precancerous lesion (intestinal metaplasia). The conventional diagnostic methods are ineffective in reliably detecting potentially treatable lesions. Investigators propose the use of vital chromoendoscopy with acetic acid using the simplified classification of Portsmouth looking for areas with loss of acetowhitening and taking targeted biopsies to increase the detection of esophageal neoplastic lesions.Read full original descriptionShow less
Acetic Acid vs Seattle Protocol for Neoplastic Lesions in Barrett Esophagus
Barrett's esophagus is a complication of chronic gastroesophageal reflux disease that occurs in up to 10% to 15% of patients with this pathology. Well-defined risk factors have been established and are important because they are considered a precancerous lesion (intestinal metaplasia). The conventional diagnostic methods are ineffective in reliably detecting potentially treatable lesions. Investigators propose the use of vital chromoendoscopy with acetic acid using the simplified classification of Portsmouth looking for areas with loss of acetowhitening and taking targeted biopsies to increase the detection of esophageal neoplastic lesions.
Inclusion: Confirmed histological diagnosis of intestinal metaplasia in follow-up protocol without dysplasia; Patients whose endoscopic image is suggestive of esophageal intestinal metaplasia and is confirmed by histology; Barrett's esophagus minimally 2cm; Patients over 18 years of age who wish to participate in the study; Signed informed consent.
Exclusion: History of esophageal ablative therapy; Known allergy or intolerance to proton pump inhibitors or acetic acid; Uncontrolled coagulopathy (INR> 1.5 or platelets <50,000); Histological evidence of esophageal adenocarcinoma or known with dysplasia; Evidence of esophageal varices; Los Angeles esophagitis C or D; Pregnancy; No authorization of informed consent.